Healthcare costs associated with initial maintenance therapy with fluticasone propionate 250 μg/salmeterol 50 μg combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPD

Journal of Medical Economics

Volumn 12, Issue 4, 2009, Pages 339-347

  Dalal, Anand A ^a   Petersen, Hans ^b   Simoni Wastila, Linda ^c   Blanchette, Christopher M ^b,d  

^a GLAXOSMITHKLINE   (United States)

^b LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Bronchodilator; Chronic obstructive pulmonary disease (COPD); Corticosteroid; Cost; Fluticasone salmeterol; Pharmacoeconomics

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; LEUKOTRIENE; LINCOMYCIN; MACROLIDE; PENICILLIN G; QUINOLONE DERIVATIVE; SULFATRIMETHOPRIM; TETRACYCLINE DERIVATIVE; THEOPHYLLINE; TIOTROPIUM BROMIDE; XANTHINE DERIVATIVE;

AGED; ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COST CONTROL; ELDERLY CARE; EMERGENCY WARD; EMPHYSEMA; FEMALE; FOLLOW UP; HEALTH CARE COST; HOSPITAL PATIENT; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICARE; OBSERVATIONAL STUDY; OUTPATIENT; RETROSPECTIVE STUDY; UNITED STATES;

AGED; ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; INSURANCE CLAIM REVIEW; IPRATROPIUM; MALE; MEDICARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SCOPOLAMINE DERIVATIVES; UNITED STATES;

EID: 72749126548     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990903369135     Document Type: Article

References (31)

1. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 2002;121(5 Suppl):121-6S.
2. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2006;343:269-280
3. Foster TS, Miller JD, Marton JP, et al. Assessment of the economic burden of COPD in the US: a review and synthesis of the literature. COPD 2006;3:211-218
4. Menzin J, Boulanger L, Marton J, et al. The economic burden of chronic obstructive pulmonary disease (COPD) in a US Medicare population. Respir Med 2008;102:1248-1256
5. American Lung Association. Research on chronic obstructive pulmonary disease. Available at: http://lungaction.org/lungusa/alert-description.html? alert-id=2956848. Accessed: 27 January 2009.
6. Global Initiative for Chronic Obstructive Lung Disease. Executive Summary. National Institutes of Health: National Heart, Lung, and Blood Institute. Updated 2008. Available at: http://www.goldcopd.com/Guidelineitem. asp?l1=2&l2=1&intId=2003. Accessed 27 January 2009.
7. MacIntyre N, Huang YC. Acute exacerbations and respiratory failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008;5:530-535
8. Grasso ME, Weller WE, Shaffer TJ, et al. Capitation, managed care, and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:133-138
9. Hilleman DE, Dewan N, Malesker M, et al. Pharmacoeconomic evaluation of COPD. Chest 2000;118:1278-1285
10. Mapel DW, Hurley JS, Frost FJ, et al. Health care utilization in chronic obstructive pulmonary disease. A case-control study in a Health Maintenance Organization. Arch Intern Med 2000;160:2653-2658
11. Strassels SA, Smith DH, Sullivan SD, et al. The costs of treating COPD in the United States. Chest 2001;119:344-352
12. Halpern MT, Stanford RH, Borker R. The burden of COPD in the USA: results from the Confronting COPD survey. Respir Med 2003;97(Suppl C):S81-9.
13. Tsai C-L, Sobrino JA, Camargo CA. National study of emergency department visits for acute exacerbation of chronic obstructive pulmonary disease, 1993-2005. Acad Emerg Med 2008;15:1275-1283
14. Mapel DW, Dedrick D, Davis K. Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration Medical System, 1991-1999. COPD 2005;2:35-41.
15. Decramer M, Nici L, Nardini S, et al. Targeting the COPD exacerbation. Respir Med 2008;102(Suppl 1):S3-15.
16. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81.
17. Calverley PM, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-456
18. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789
19. Ferguson GR, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 μg) or salmeterol (50 μg) on COPD exacerbations. Respir Med 2008;102:1099-1108
20. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26.
21. Lee TA, Wilke C, Joo M, et al. Outcomes associated with tiotropoium use in patients with chronic obstructive pulmonary disease. Arch Intern Med 2009;169:1403-1410
22. Soriano JB, Kiri VA, Pride NB, et al. Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 2003;2:67-74.
23. Rascati KL, Stanford RH, Borker R. A comparison of the risk of hospitalizations due to chronic obstructive pulmonary disease in Medicaid patients with various medication regimens, including ipratropium, inhaled corticosteroids, salmeterol, or their combination. Clin Ther 2005;27:346-354
24. Rascati KL, Akazawa M, Johnsrud M, et al. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen. Clin Ther 2007;29:1203-1213
25. Akazawa M, Hayflinger DC, Stanford RH, et al. Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease. Am J Manag Care 2008;14:438-448
26. Blanchette CM, Akazawa M, Dalal A, et al. Risk of hospitalizations/ emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 μg/salmeterol 50 μg compared with ipratropium for chronic obstructive pulmonary disease in older adults. Am J Geriatr Pharmacother 2008;6:138-146
27. National Heart, Lung, and Blood Institute. 2007 NHLBI morbidity and mortality chartbook. Bethesda, Maryland: US Department of Health and Human Service, National Institutes of Health. 2007. Available at: http://www.nhlbi. nih.gov/resources/docs/cht-book.htm. Accessed 30 January 2009.
28. US Department of Labor. Bureau of Labor Statistics. Consumer Price Indexes. Available at: http://www.bls.gov\CPI. Accessed 21 September 2009.
29. Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009;64:728-735
30. Blanchette CM, Gutierrez B, Ory C, et al. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population. J Manag Care Pharm 2008;14:176-185
31. Make B, Hanania NA, ZuWallack R, et al. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. Clin Ther 2005;27:531-542